Industry RegionalBanks
This price move could be a signal that USCB may fall back below the higher band and head toward the middle band. Traders may consider selling the stock, shorting the stock, or exploring put options. A.I.dvisor backtested 44 similar cases where USCB's price broke its higher Bollinger Band, and of them led to a successful outcome. Odds of Success:
The Aroon Indicator for USCB entered a downward trend on October 27, 2026. Tickeron's A.I.dvisor identified a pattern where the AroonDown red line was above 70 while the AroonUp green line was below 30 for three straight days. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options. A.I.dvisor looked at 157 similar instances where the Aroon Indicator formed such a pattern. In 108 of the 157 cases the stock moved lower. This puts the odds of a downward move at 69%.
USCB moved below its 50-day moving average on October 23, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where USCB declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 64%.
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where USCB's RSI Oscillator exited the oversold zone, 20 of 24 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 83%.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 11 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
The Momentum Indicator moved above the 0 level on November 11, 2026. You may want to consider a long position or call options on USCB as a result. In 71 of 111 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 64%.
The Moving Average Convergence Divergence (MACD) for USCB just turned positive on November 11, 2026. Looking at past instances where USCB's MACD turned positive, the stock continued to rise in 35 of 47 cases over the following month. The odds of a continued upward trend are 74%.
Following a +1.11% 3-day Advance, the price is estimated to grow further. Considering data from situations where USCB advanced for three days, in 185 of 263 cases, the price rose further within the following month. The odds of a continued upward trend are 70%.
USCB may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Tickeron PE Growth Rating for this company is 30 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 38 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 56, placing this stock slightly better than average.
The Tickeron SMR rating for this company is 42 (best 1 - 100 worst), indicating slightly weaker than average sales and a marginally profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is 58 (best 1 - 100 worst), indicating fairly steady price growth. USCB’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 60 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.558) is normal, around the industry mean (1.262). P/E Ratio (12.609) is within average values for comparable stocks, (13.479). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.190). Dividend Yield (0.025) settles around the average of (0.035) among similar stocks. P/S Ratio (4.421) is also within normal values, averaging (3.738).